Wild-type Reovirus

BIOLOGICAL8 trials

Conditions

Childhood AstrocytomaChildhood Atypical Teratoid/Rhabdoid TumorDiffuse Intrinsic Pontine GliomaGliomaLight Chain Deposition DiseasePancreatic Acinar Cell CarcinomaPancreatic AdenocarcinomaPancreatic Ductal Adenocarcinoma

Phase 1

Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy

CompletedNCT00602277

National Cancer Institute (NCI)Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma

Start: 2008-04-30End: 2016-08-31Updated: 2016-08-08

Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors

CompletedNCT01240538

National Cancer Institute (NCI)Unspecified Childhood Solid Tumor, Protocol Specific

Start: 2010-12-31Updated: 2014-05-13

Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma

CompletedNCT01533194

National Cancer Institute (NCI)Light Chain Deposition Disease, Refractory Plasma Cell Myeloma

Start: 2012-04-30End: 2015-02-28Updated: 2015-04-15

Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors

CompletedNCT02444546

Mayo ClinicChildhood Astrocytoma, Childhood Atypical Teratoid/Rhabdoid Tumor, Diffuse Intrinsic Pontine Glioma +7

Start: 2015-06-21End: 2022-11-21Updated: 2023-04-24

Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

CompletedNCT02514382

University of Southern CaliforniaRecurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma

Start: 2015-08-21End: 2022-04-19Updated: 2023-08-14

Phase 2

Viral Therapy in Treating Patients With Metastatic Melanoma

CompletedNCT00651157

National Cancer Institute (NCI)Recurrent Melanoma, Stage IV Melanoma

Start: 2008-04-30End: 2012-10-31Updated: 2014-04-22

Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

CompletedNCT01280058

National Cancer Institute (NCI)Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Pancreatic Carcinoma +1

Start: 2010-12-31End: 2016-01-20Updated: 2018-03-09

Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer

TerminatedNCT03723915

Northwestern UniversityPancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8

Start: 2018-11-14End: 2021-04-24Updated: 2022-10-05

Journal of Clinical Oncology2024-01-20

Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial

Clinical Cancer Research2023-10-0912 citations

Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC).

2023-07-1317 citations

Treatment with pembrolizumab in combination with the oncolytic virus pelareorep promotes anti-tumor immunity in patients with advanced pancreatic adenocarcinoma.

Journal of Clinical Oncology2021-05-203 citations

Abstract PO-022: Plasma fatty acid levels in treatment-naïve metastatic pancreatic cancer patients are associated with clinical indicators of cachexia

Cancer Research2020-11-13

Pembrolizumab in combination with the oncolytic virus pelareorep in patients progressing on systemic chemotherapy for advanced pancreatic adenocarcinoma: A phase II study.

Journal of Clinical Oncology2020-05-201 citations

CEACAM6 as a candidate biomarker for pelareorep sensitivity in pancreatic adenocarcinoma (PDAC).

Journal of Clinical Oncology2020-02-01

Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma

Molecular Therapy2016-04-04150 citations

Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer (mPC).

Journal of Clinical Oncology2015-01-201 citations

Wild-type Reovirus

Sponsors

Conditions

Phase 1

Phase 2

Related Papers